U.S. stock market update: Propanc Biopharma down 8.57%

U.S. Stock Market Midday Update Propanc Biopharma, down 8.57%, with increased trading volume. Based on recent key news: On August 25, Propanc Biopharma announced that its main asset "PRP" is about to enter Phase 1B clinical trials, raising market concerns about its funding needs and dilution risks, leading to an 8.57% drop in stock price. On August 25, there was increased market focus on financing and trial expansion for small biotech companies, with Propanc facing dilution risks that affected investor confidence. On August 25, Propanc provided a shareholder update that failed to alleviate market concerns about its financial situation, further exacerbating stock price volatility. Top Stocks by Industry Trading Volume Allarity Therapeutics rose 132.13%, with a trading volume of $493 million. Based on recent important news: On August 26, the U.S. FDA granted Allarity Therapeutics' ovarian cancer therapy Stenoparib Fast Track designation, driving the stock price up 42%. On August 26, Stenoparib obtained global development and commercialization rights, further boosting market confidence. On August 26, the FDA's Fast Track designation helps accelerate drug development and review, enhancing investor confidence. Futai Pharmaceutical fell 0.72%, with increased trading volume. Based on recent important news: On August 25, Tianma Technology adjusted its seedling strategy to seize the opportunity of abundant Japanese eel seedlings, improving the company's profitability, which affected Futai Pharmaceutical's stock price, leading to a 0.72% decline. On August 24, the Chinese stock market was severely undervalued, suppressing investor enthusiasm for buying, leading to increased market volatility and a decline in Futai Pharmaceutical's stock price. On August 23, senior executives of Dameng Data were investigated, undermining market confidence and affecting Futai Pharmaceutical's stock price volatility. Argenx rose 3.25%, with a trading volume of $111 million. Based on recent key news: On August 25, Argenx announced that Vyvgart achieved positive top-line results in the ADAPT SERON study and plans to submit an sBLA application to the FDA by the end of the year, resulting in a 3.25% increase in stock price. On August 25, RBC Capital set a target price of $850 for Argenx, further driving the stock price up. On August 25, Vyvgart Hytrulo pre-filled syringes were approved for self-injection, boosting market confidence. Top Stocks by Industry Market Capitalization AbbVie fell 0.14%, with increased trading volume. Based on recent important news: On August 25, AbbVie announced the acquisition of Gilgamesh's antidepressant bretisilocin for $1.2 billion, aiming to expand its psychiatric treatment drug pipeline, resulting in a slight decline of 0.14% in stock price On August 26, AbbVie reached an agreement with Gilgamesh to acquire its core candidate drug bretisilocin, and the market's reaction to the deal was relatively cautious. On August 26, analysts maintained their rating on AbbVie, with a target price between $231 and $255, and market sentiment remained stable